Global Flavoxate Hydrochloride Tablets Market Drivers
Key players are focusing on manufacturing of drugs in the global flavoxate hydrochloride tablets market. Several generic players have launched their products after the patent expiration of Urispas in the year 2004, manufactured by Janssen Pharmaceuticals, Inc. For instance, companies such as Paddock Laboratories LLC and Epic Pharma LLC launched generic products for Urispas, which are cheaper than branded products in the year 2004 and 2011, respectively.
Increasing incidence of lower urinary tract dysfunction such as prolonged micturition, incomplete bladder emptying, and others are expected to support growth of the market. For instance, according to a review article by Investigative and Clinical Urology, 2017, globally, around 10% of the geriatric population is suffering from urine incontinency while it is estimated to reach 20% by 2050. According to the same source, in South Korea, in population aged 70 years above, 48% of men and 12% of women are expected to suffer from detrusor contractile dysfunction in 2017. As per the Central Medicare and Medicaid Services (CMS), U.S., around US$ 8,800 million of flavoxate hydrochloride tablets have been consumed in the year 2017 by patients in U.S. suffering from insomnia. These factors are expected to support the global flavoxate hydrochloride tablets market growth over the forecast period.
Market Taxonomy
By Medicine Type
By Distribution Channel
By Region
Flavoxate Hydrochloride Tablets Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients